Astrazeneca Regulatory News (AZN)

26 June 2018 07:00 BST

BOARD COMMITTEE CHANGES

AstraZeneca PLC (the Company) today announced the following Board Committee changes.

Science Committee:

With effect from 1 July 2018, Nazneen Rahman will become permanent Chairman of the Science Committee. Professor Rahman joined the Science Committee on her appointment as a Director on 1 June 2017 and has been interim Chairman of the Committee since November 2017.

Audit Committee:

With effect from 30 June 2018, Shriti Vadera will step down as a member of the Audit Committee. As previously announced, Shriti Vadera has informed the Board that she will retire as a Director by 31 December 2018. With effect from 1 November 2018, Deborah DiSanzo will become a member of the Audit Committee.

Remuneration Committee:

With effect from 1 July 2018, Sheri McCoy will become a member of the Remuneration Committee.

Nomination and Governance Committee:

With effect from 1 July 2018, Nazneen Rahman will become a member of the Nomination and Governance Committee.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Adrian KempCompany Secretary

AstraZeneca PLC